Drug Screening Market Research, 2026

The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period. Growth in this market is attributed to the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

Browse in-depth TOC on "Drug Screening Market"
228 – Tables
36 – Figures
223 – Pages

The drug screening market refers to the industry involved in the development and deployment of various methods and technologies for detecting the presence of drugs or their metabolites in biological samples, such as urine, blood, saliva, or hair.

Drug screening is primarily used in several contexts, including:

Workplace Drug Testing: Many employers require their employees to undergo drug screening as part of pre-employment checks or random testing to ensure a safe and drug-free work environment.

Sports and Athletics: Athletes in competitive sports often undergo drug testing to prevent the use of performance-enhancing substances that could give them an unfair advantage.

Criminal Justice: Drug screening is used in the criminal justice system to monitor individuals on probation or parole, as well as in correctional facilities.

Clinical and Healthcare: Healthcare providers may use drug screening to monitor patients prescribed with controlled substances and to diagnose and treat substance use disorders.

Drug Development: Pharmaceutical companies and research organizations use drug screening to test the efficacy and safety of new drugs in preclinical and clinical trials.

Browse Complete Report @  https://www.marketsandmarkets.com/Market-Reports/drug-alcohol-screening-market-162987773.html

Key Market Players

The drug screening market is highly competitive and populated by several big and small players. Prominent players offering drug screening products and services include LabCorp (US), Quest Diagnostics (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Alfa Scientific Designs, Inc. (US),  OraSure Technologies, Inc. (US), Siemens Healthineers (Germany), Roche (Switzerland), MPD Inc. (US), Shimadzu (Japan), LifeLoc Technologies (US), Drägerwerk (Germany), Premier Biotech, Inc. (US), Omega Laboratories, Inc. (US), Psychemedics (US), Clinical Reference Laboratory (US), American Bio Medica Corporation (US), ACM Global Laboratories (US), CareHealth America Corp (US), Sciteck, Inc. (US), Synens (France), Intoximeters (US), AccuSource (US), Cordant Health Solutions (US), Millennium Health (US).

LabCorp (US): LabCorp is a leading player in the US drug screening services market. The company’s leading position is attributed to its wide drug testing portfolio, including over 4,800 tests. The company has a strong brand name and robust service portfolio, which provides drug screening services to managed care organizations, governmental agencies, healthcare providers, hospitals and health systems, employers, patients, consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories.

Abbott Laboratories (US): Abbott Laboratories has a strong product portfolio, and its FDA and CE Mark-approved products have helped the company enhance its presence in the drug screening market. Abbott provides abuse testing products and services for many settings such as hospitals, physician offices, criminal justice agencies, workplaces, rehabilitation centers, occupational health clinics, and homes.

North America is expected to dominate the market with a share of 48.2%, followed by Europe.

The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=162987773

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com